TY  - BOOK
AU  -       Edina Cosmas Makelele
AU  -       Beda Likonda 
TI  - Overall Survival, Recurrence Rates and Toxicities among Cervical Cancer Patients Who Received Concurrent Chemoradiotherapy at Bugando Cancer Center
PY  - 2023///
CY  - Mwanza, Tanzania: 
PB  - Catholic University of Health and Allied Sciences [CUHAS – Bugando] : 
KW  -  
N2  - Abstract
Background: Cervical cancer is the fourth most common disease in women worldwide and  Concurrent chemo-radiotherapy (CCRT) has been recommended as the standard treatment for local advanced cervical cancer. However, for cervical cancer patients at BMC/BCC, studies or information's on patients outcome after CCRT are limited. The study retrospectively determine the overall survival rates, recurrence rates and toxicities among cervical cancer patients who received concurrent chemo-radiotherapy at Bugando Cancer Centre.

Methods: A sample of 269 cervical cancer patients  who received CCRT at BCC from 2018 to 2022 were retrospectively analyzed to determine overall survival, recurrence rates and toxicities among cervical cancer patients. Data were collected through a designed checklist and analyzed using the Statistical Package for the Social Sciences (SPSS) version 20 software where by the survival rates were presented using kaplan-meier curves.

Results: Mean survival duration was 25.6 months with standard error of 1.2 and confidence interval of 23.3 to 27.8 months. The 2-years overall survival (OS) was 82.9% and The proportion of the study participants who were found died at the end of study were 46(17.1%) but Most of patients 258(95.9%) had no recurrence.Also majority of the study participant had less severe side effects. The comparatively severe form were experienced among mucositits 154(57.2%) and chronic proctitis (hematochezia) 110(40.9%) in grade II.

Conclusion: Concurrent chemo-radiotherapy for patients with cervical cancer produced good efficacy or outcome with mild side effects and recurrences indicating its effectiveness in treating cervical cancer.

ER  -